Get the Stockscreener App
1.18
2.61%
0.03
After Hours:
1.17
-0.01
-0.85%
Lucid Diagnostics Inc stock is traded at $1.18, with a volume of 1.26M.
It is up +2.61% in the last 24 hours and up +14.56% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.15
Open:
$1.16
24h Volume:
1.26M
Relative Volume:
1.05
Market Cap:
$161.93M
Revenue:
$4.35M
Net Income/Loss:
$-45.53M
P/E Ratio:
-1.0926
EPS:
-1.08
Net Cash Flow:
$-44.79M
1W Performance:
+14.56%
1M Performance:
+14.56%
6M Performance:
+0.85%
1Y Performance:
+50.63%
1-Day Range:
$1.14
$1.2699
1-Week Range:
$1.025
$1.2699
52-Week Range:
$0.7501
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.18 | 117.18M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
131.38 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.95 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.92 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.58 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Can Lucid Diagnostics Inc. stock sustain revenue growthCEO Change & Growth Oriented Trading Recommendations - newser.com
Is Lucid Diagnostics Inc. trending in predictive chart modelsIPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Understanding Lucid Diagnostics Inc.’s price movementPortfolio Value Report & Safe Entry Trade Signal Reports - newser.com
Is Lucid Diagnostics Inc. stock oversold or undervaluedJuly 2025 Opening Moves & Expert Curated Trade Setups - newser.com
Lucid Diagnostics Stock Sinks After-Hours On Equity Raise, But Retail Dives In Anyway - MSN
What MACD and RSI say about Lucid Diagnostics Inc.July 2025 PreEarnings & Community Shared Stock Ideas - newser.com
Using flow based indicators on Lucid Diagnostics Inc.Trade Volume Summary & High Win Rate Trade Alerts - newser.com
Lucid Diagnostics Inc Stock Analysis and ForecastTechnical Breakout Signals & Double Digit Wealth Tips - earlytimes.in
Can Lucid Diagnostics Inc. recover in the next quarterWeekly Market Outlook & Fast Exit and Entry Trade Guides - newser.com
How sentiment analysis helps forecast Lucid Diagnostics Inc.Portfolio Update Report & Expert Approved Momentum Trade Ideas - newser.com
Earnings visualization tools for Lucid Diagnostics Inc.Weekly Market Summary & Fast Entry High Yield Tips - newser.com
PAVmed subsidiary Veris Health launches cancer care platform at OSU center - Investing.com Canada
Lucid Diagnostics (NASDAQ:LUCD) Price Target Raised to $8.00 - MarketBeat
Ascendiant Capital Maintains Lucid Diagnostics (LUCD) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for Lucid Diagnostics (LU - GuruFocus
Will Lucid Diagnostics Inc. stock benefit from automationMarket Weekly Review & Verified Chart Pattern Trade Signals - newser.com
Can Lucid Diagnostics Inc. stock beat analyst upgradesWeekly Trend Recap & Comprehensive Market Scan Insights - newser.com
Lucid Diagnostics (NASDAQ:LUCD) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
What sentiment indicators say about Lucid Diagnostics Inc. stockJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - newser.com
What recovery options are there for Lucid Diagnostics Inc.Weekly Market Report & Reliable Price Breakout Signals - newser.com
Reversal indicators forming on Lucid Diagnostics Inc. stockInsider Selling & Consistent Profit Alerts - newser.com
Will a bounce in Lucid Diagnostics Inc. offer an exit2025 Top Gainers & Trade Opportunity Analysis - newser.com
Identifying reversal signals in Lucid Diagnostics Inc.Earnings Trend Report & Daily Technical Forecast Reports - newser.com
Tick level data insight on Lucid Diagnostics Inc. volatilityTrade Performance Summary & AI Driven Stock Reports - newser.com
Brokerages Set Lucid Diagnostics Inc. (NASDAQ:LUCD) PT at $3.65 - Defense World
Altoona firefighters receive cancer screenings - WJAC
Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Published on: 2025-09-29 09:04:08 - newser.com
Lucid Diagnostics: Holding Onto Medicare Coverage Hopes (NASDAQ:LUCD) - Seeking Alpha
Published on: 2025-09-29 01:30:08 - newser.com
What analysts say about Lucid Diagnostics Inc stockTrendline Breakouts & Low Cost Capital Growth - earlytimes.in
Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen - MarketBeat
Published on: 2025-09-27 23:30:42 - newser.com
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lucid Diagnostics Inc Stock (LUCD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
May 20 '25 |
Buy |
1.29 |
187,098 |
242,292 |
187,098 |
| Matheis Dennis | Director |
May 21 '25 |
Buy |
1.32 |
129,684 |
171,520 |
316,782 |
| Matheis Dennis | Director |
May 22 '25 |
Buy |
1.32 |
33,218 |
43,795 |
350,000 |
0.01%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):